Yamin ‘Mo’ Khan, CEO of hVIVO, presents at the UK Investor Magazine Investor Conference at the London Stock Exchange 13th March 2024.
Download Presentation Slides here
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
